­
­
­
­

Inventi Impact: Pharm Analysis & Quality Assurance

Articles

  • Inventi:ppaqa/24067/17
    New Modified UPLC/Tandem Mass Spectrometry Method for Determination of Risperidone and Its\nActive Metabolite 9-Hydroxyrisperidone in Plasma: Application to Dose-Dependent\nPharmacokinetic Study in Sprague-Dawley Rats
    01-Jan-1970 Research 2017 : October - December
    Essam Ezzeldin, Marwa Tammam, Nisreen F Abo Talib

    Sensitive and specific liquid-chromatography tandem mass spectrometry (UPLC-MS/MS) assay has been developed and validated\nfor simultaneous quantification of risperidone (RIS) and its active metabolite 9-hydroxyrisperidone (9-OH-RIS) in rat plasma using\nolanzapine (OLA) as internal standard (IS). Pharmacokinetics of risperidone and its active metabolite 9-hydroxyrisperidone was\ncompared across different doses (0.3, 1.0, and 6.0mg/kg). Serial blood sample was collected over a time of 48 hours and analyzed\nfor risperidone and its active metabolite 9-hydroxyrisperidone.The pharmacokinetics parameters including

    How to Cite this Article
    CC Compliant Citation: Essam Ezzeldin, Marwa Tammam, and Nisreen F. Abo Talib, â??New Modified UPLC/Tandem Mass Spectrometry\nMethod for Determination of Risperidone and Its Active Metabolite 9-Hydroxyrisperidone in Plasma: Application to Dose-Dependent\nPharmacokinetic Study in Sprague-Dawley Rats,â? International Journal of Analytical Chemistry, vol. 2017, Article ID 1271383, 11 pages,\n2017. doi:10.1155/2017/1271383, http://creativecommons.org/licenses/by/4.0/.
    Download Full Text